Once the decision to start HRT is made, a second decision follows immediately and gets far less airtime: how the oestrogen should enter your body. Gel rubbed into skin, a patch changed twice a week, a daily spray, or a tablet swallowed with breakfast. The hormone at the end of each route is the same; what changes is the journey, and the journey turns out to matter, for clot risk, for steadiness of effect, and for how sustainable the routine feels across years of use. Modern UK practice has a clear default and good reasons for every exception to it.
Why the route changes the risk
The pivotal difference is a piece of plumbing called first-pass metabolism. Swallowed oestrogen is absorbed from the gut and delivered first to the liver at high concentration, where it nudges up the production of clotting factors before reaching the rest of the body. That is why oral HRT is associated with a raised risk of venous thromboembolism, roughly doubled in observational data, though the absolute numbers remain small for most women. Oestrogen absorbed through the skin, from gel, patch or spray, enters the bloodstream directly, skips the concentrated liver visit, and large studies show no meaningful increase in clot risk at standard doses. UK guidance therefore steers women with any clot-relevant history, higher BMI, migraine, or simply a preference for the lower-risk route towards transdermal delivery, and in practice it has become the default for new starters. The symptom relief, importantly, is equivalent once dosing is right; nobody sacrifices effectiveness by choosing skin over stomach.
Patches: steady and low-effort
The patch is the set-and-forget option: stuck below the waistline and changed twice a week, it releases oestrogen at a steady rate around the clock, producing the most stable blood levels of any format. That steadiness suits women whose symptoms flare with hormonal dips, and the twice-weekly rhythm suits anyone who distrusts daily routines. The drawbacks are practical rather than medical: some skins itch or mark under adhesive, patches can peel at the edges in heat, pools and gyms test their adhesion, and a visible rectangle bothers some wearers. Rotating sites, pressing firmly for ten seconds, and applying to clean, cream-free skin solve most adhesion complaints, and a half-fallen patch replaced early costs nothing but a spare from the box. Combined patches containing both oestrogen and progestogen exist, folding womb protection into the same rectangle for those who suit the doses on offer.
Gels and sprays: daily control
Gel, in pump or sachet form, is rubbed into the outer arm or thigh once daily and dries in a minute or two; a metered spray does the same job faster on a forearm. Their shared virtue is adjustability: doses titrate in small steps, which makes them favourites for perimenopausal women whose own fluctuating hormones need topping up delicately, and for anyone fine-tuning around symptoms. Skin reactions are rarer than with adhesive. The costs are behavioural: a daily task to remember, a short wait before dressing, and the need to avoid washing the site or transferring gel to partners, children or pets before it absorbs. Women who travel constantly sometimes find pump bottles less convenient than a strip of patches; women who swim daily often find them more so. Between patch and gel, effectiveness and safety are equivalent; the deciding vote belongs to the routine you will actually keep, which is a question about your mornings, not your hormones.
Tablets: where they still make sense
Oral HRT has not been retired; it has been repositioned. For a younger, lean, non-smoking woman without migraine or clot history, the absolute clot risk on tablets remains small, and the one-pill simplicity, often combining oestrogen and progestogen in a single daily tablet, fits some lives better than anything applied to skin. Tablets also suit women who react to adhesives and dislike gels. The women for whom tablets are the wrong answer are well defined: previous clots or strong family history, thrombophilia, higher BMI, migraine with aura, significant cardiovascular risk factors, smokers, and generally those starting HRT later, where the transdermal advantage matters most. One further nuance: oral oestrogen's liver passage slightly raises triglycerides and binding proteins, occasionally relevant to thyroid dosing and lipid management, another quiet argument for skin routes in complex medication pictures. A proper consultation walks this list; the format decision is individual risk arithmetic, not fashion.
Choosing, switching and giving it time
A sensible decision path: transdermal by default, patch if you want minimum effort and maximum steadiness, gel or spray if you want fine control or hate adhesives, tablet if your risk profile is clean and a pill is the routine you will keep. Then hold the plan long enough to judge it fairly, since dose-finding usually takes a few months of adjustment, and most early wobbles turn out to be dose issues rather than format failures. Switching between formats is routine and low-drama: patches to gel, gel to spray, oral to transdermal, adjusted at review against symptoms and any side effects like skin irritation or breast tenderness. Nothing about the first choice is binding, and the best format is ultimately the one that keeps oestrogen arriving reliably through years of real life, holidays, gym bags and forgetful weeks included. For the patch specifics, our complete guide to HRT patches goes deeper, and for the wider treatment picture, our guides to perimenopause symptoms and how long menopause lasts set the context.
